-
Je něco špatně v tomto záznamu ?
Comparative Study of Latanoprost Drug Delivery Systems for Glaucoma Treatment and Their Interaction with the Tear Film Lipid Layer Models
MC. Saija, K. Vazdar, W. Pajerski, A. Olżyńska, P. Daull, JS. Garrigue, L. Cwiklik
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- antihypertenziva terapeutické užití MeSH
- glaukom * farmakoterapie MeSH
- latanoprost terapeutické užití MeSH
- lékové transportní systémy MeSH
- lidé MeSH
- nitrooční tlak MeSH
- oči * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
This study investigates the interaction of two approved and one newly developed latanoprost formulation with in vitro and in silico models of the tear film and tear film lipid layer (TFLL). Latanoprost, a prostaglandin analogue used for intraocular elevated pressure treatment, is topically delivered by nanocarriers within aqueous solutions or emulsions. The study focuses on the impact of these carriers on drug interactions with the tear film and their effect on the TFLL. Three different types of latanoprost carriers, micellar, nanoemulsion, and polymer-based, were compared, and each revealed distinct interaction patterns with the TFLL. Surface pressure kinetics demonstrated a rapid increase for the benzalkonium chloride formulation and a slow rise for the preservative-free variants. Visualization of the acellular in vitro TFLL model revealed different patterns of incorporation for each formulation, indicating unique interaction mechanisms. Molecular dynamics simulations further revealed different mechanisms of drug release in the TFLL between micellar and nanoemulsion formulations. In-depth examination highlighted the role of triglyceride molecules in replenishing the nonpolar layer of the TFLL, which suggests potential improvements in ocular surface compatibility by adjusting the quality and concentration of the oily phase. These findings suggest the potential for optimizing latanoprost formulations by tuning the oily phase-to-surfactant ratio and selecting suitable surfactants.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24007735
- 003
- CZ-PrNML
- 005
- 20240423160221.0
- 007
- ta
- 008
- 240412s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acs.molpharmaceut.3c00635 $2 doi
- 035 __
- $a (PubMed)38110329
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Saija, Maria Chiara $u J. Heyrovský Institute of Physical Chemistry, Czech Academy of Sciences, Dolejškova 3, 18223 Prague, Czech Republic $u Department of Physical and Macromolecular Chemistry, Faculty of Science, Charles University, Hlavova 8, 12800 Prague, Czech Republic
- 245 10
- $a Comparative Study of Latanoprost Drug Delivery Systems for Glaucoma Treatment and Their Interaction with the Tear Film Lipid Layer Models / $c MC. Saija, K. Vazdar, W. Pajerski, A. Olżyńska, P. Daull, JS. Garrigue, L. Cwiklik
- 520 9_
- $a This study investigates the interaction of two approved and one newly developed latanoprost formulation with in vitro and in silico models of the tear film and tear film lipid layer (TFLL). Latanoprost, a prostaglandin analogue used for intraocular elevated pressure treatment, is topically delivered by nanocarriers within aqueous solutions or emulsions. The study focuses on the impact of these carriers on drug interactions with the tear film and their effect on the TFLL. Three different types of latanoprost carriers, micellar, nanoemulsion, and polymer-based, were compared, and each revealed distinct interaction patterns with the TFLL. Surface pressure kinetics demonstrated a rapid increase for the benzalkonium chloride formulation and a slow rise for the preservative-free variants. Visualization of the acellular in vitro TFLL model revealed different patterns of incorporation for each formulation, indicating unique interaction mechanisms. Molecular dynamics simulations further revealed different mechanisms of drug release in the TFLL between micellar and nanoemulsion formulations. In-depth examination highlighted the role of triglyceride molecules in replenishing the nonpolar layer of the TFLL, which suggests potential improvements in ocular surface compatibility by adjusting the quality and concentration of the oily phase. These findings suggest the potential for optimizing latanoprost formulations by tuning the oily phase-to-surfactant ratio and selecting suitable surfactants.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a latanoprost $x terapeutické užití $7 D000077338
- 650 12
- $a oči $7 D005123
- 650 _2
- $a nitrooční tlak $7 D007429
- 650 12
- $a glaukom $x farmakoterapie $7 D005901
- 650 _2
- $a lékové transportní systémy $7 D016503
- 650 _2
- $a antihypertenziva $x terapeutické užití $7 D000959
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Vazdar, Katarina $u J. Heyrovský Institute of Physical Chemistry, Czech Academy of Sciences, Dolejškova 3, 18223 Prague, Czech Republic $1 https://orcid.org/0000000349527965
- 700 1_
- $a Pajerski, Wojciech $u J. Heyrovský Institute of Physical Chemistry, Czech Academy of Sciences, Dolejškova 3, 18223 Prague, Czech Republic
- 700 1_
- $a Olżyńska, Agnieszka $u J. Heyrovský Institute of Physical Chemistry, Czech Academy of Sciences, Dolejškova 3, 18223 Prague, Czech Republic $1 https://orcid.org/0000000165335280
- 700 1_
- $a Daull, Philippe $u SANTEN SAS, Novagali Innovation Center, 1 rue Pierre Fontaine, Bâtiment Genavenir IV, Evry Cedex F-91458, France
- 700 1_
- $a Garrigue, Jean-Sebastien $u SANTEN SAS, Novagali Innovation Center, 1 rue Pierre Fontaine, Bâtiment Genavenir IV, Evry Cedex F-91458, France
- 700 1_
- $a Cwiklik, Lukasz $u J. Heyrovský Institute of Physical Chemistry, Czech Academy of Sciences, Dolejškova 3, 18223 Prague, Czech Republic $1 https://orcid.org/0000000220838738
- 773 0_
- $w MED00008279 $t Molecular pharmaceutics $x 1543-8392 $g Roč. 21, č. 1 (2024), s. 126-136
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38110329 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423160218 $b ABA008
- 999 __
- $a ok $b bmc $g 2081614 $s 1217502
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 21 $c 1 $d 126-136 $e 20231218 $i 1543-8392 $m Molecular pharmaceutics $n Mol Pharm $x MED00008279
- LZP __
- $a Pubmed-20240412